Compare Honeywell International Inc (HON) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Honeywell International Inc vs Repligen Corporation Common Stock — how do they compare? Honeywell International Inc trades at $208.4 (market cap $65.70B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Honeywell International Inc is far larger — about 5.9× Repligen Corporation Common Stock's market cap, and Honeywell International Inc pays a 1.35% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Honeywell International Inc for 91 Days and Repligen Corporation Common Stock for 0 Days on average.
| HON | RGEN | |
|---|---|---|
Market Cap | $65.70B | $11.14B |
Volume | 1,861,268 | 1,259,263 |
Sector | Industrials | Health |
52-Week High | $248.79 | $194.57 |
52-Week Low | $188.14 | $102.87 |
Typical Hold Time | 91 Days | 0 Days |
Enterprise Value | $90.49B | $11.02B |
Dividend Yield | 1.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Honeywell International (HON) trades at $207.61, down 0.97% on the day, as technical indicators show bearish momentum despite strong fundamentals. The company has consistently beaten earnings estimates in recent quarters with Q2 2026 EPS of $1.95 exceeding expectations of $1.83. Recent news highlights Honeywell's $300 million contract win for the Dangote refinery project and the company's strategic focus on automation following its corporate restructuring into three separate entities.
Honeywell presents a compelling value opportunity with attractive valuation multiples (P/E of 7.97, EV/EBITDA of 6.74) and strong profitability metrics (ROE 47.43%, net margin 21.58%). However, investors face risks from increasing debt levels and the execution challenges of the corporate spin-off strategy. Analyst consensus remains bullish with a $259.25 price target representing 25% upside potential from current levels.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Honeywell International Inc
Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Read more on HON →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
